We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer.
- Authors
Seung-Hyuk Shim; Jung-Yun Lee; Yoo-Young Lee; Jeong-Yeol Park; Yong Jae Lee; Se Ik Kim; Gwan Hee Han; Eun Jung Yang; Noh, Joseph J.; Ga Won Yim; Joo-Hyuk Son; Nam Kyeong Kim; Tae-Hyun Kim; Tae-Wook Kong; Youn Jin Choi; Cho, Angela; Hyunji Lim; Eun Bi Jang; Hyun Woong Cho; Dong Hoon Suh
- Abstract
In the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer: immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2) Cervical cancer: surgery in low-risk early-stage cervical cancer, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Ovarian cancer: immunotherapy, triplet therapies using immune checkpoint inhibitors along with antiangiogenic agents and PARP inhibitors, and ADCs. In 2023, the field of endometrial cancer treatment witnessed a landmark year, marked by several practice-changing outcomes with immune checkpoint inhibitors and the reliable efficacy of PARP inhibitors and ADCs.
- Subjects
IMMUNOTHERAPY; ENDOMETRIAL cancer; GYNECOLOGIC cancer; MEDICAL research; IMMUNE checkpoint inhibitors; GYNECOLOGIC oncology
- Publication
Journal of Gynecologic Oncology, 2024, Vol 35, Issue 2, p1
- ISSN
2005-0380
- Publication type
Academic Journal
- DOI
10.3802/jgo.2024.35.e66